

Edgar Filing: TRANSGENOMIC INC - Form 8-K

terminate the binding Summary of Terms, dated December 15, 2006, pursuant to which NRP had agreed to purchase 250,000 shares of common stock of Pinnacle Pharmaceuticals, Inc. from the Company. Accordingly, the Company will not be selling such shares to NRP as announced in the report on Form 8-K filed by the Company on December 21, 2006.

There are no relationships between the Company and the NRP.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TRANSGENOMIC, INC.

By /s/ Debra A. Schneider

Debra A. Schneider,
Chief Financial Officer

February 26, 2007

3